Table 1 Clinical characteristics of the subjects at baseline
Teneligliptin | Sitagliptin | P value | |
|---|---|---|---|
Age (years) | 70.0 ± 3.9 | 65.4 ± 10.7 | 0.912 |
Sex (M/F) | 22 (10/12) | 23 (12/11) | 0.652 |
Body mass index (kg/m2) | 22.1 ± 3.4 | 23.6 ± 1.9 | 0.209 |
HbA1c % (NGSP) | 8.1 ± 1.4 | 8.0 ± 1.7 | 0.739 |
Duration of diabetes (years) | 13.2 ± 3.0 | 12.8 ± 6.3 | 0.952 |
eGFR (mL/min/1.73m2) | 43.5 ± 15.8 | 39.6 ± 15.9 | 0.394 |
Urinary albumin excretion (µg/g Cre) | 418.4 (93.5–299.5) | 485.0 (67.0–729.3) | 0.750 |
Statins n (%) | 16 (72.7 %) | 17 (80.9 %) | 0.627 |
ACEI or ARB n (%) | 20 (90.1 %) | 20 (95.2 %) | 0.578 |
Biguanide n (%) | 3 (13.6 %) | 4 (19.0 %) | 0.631 |
Sulfonylurea or glinide n (%) | 7 (31.8 %) | 9 (42.9 %) | 0.454 |
Insulin n (%) | 12 (54.5 %) | 9 (42.9 %) | 0.443 |